Skip to main content

Search

COVID-19 and Higher Education

A collection of commissioned responses from individual scholars and exemplary institutional responses from universities and scholarly societies, published by the Network of Concerned Academics

Duygu Kasdogan

Duygu Kasdogan

I live in İzmir, Turkey, and am assistant professor in the Division of Urbanization and Environmental Problems at the Department of Political Science and Public Administration at İzmir Katip Çelebi University. I am also part of an STS Research Network in Turkey – IstanbuLab. I can be reached at duygukasdogan@gmail.com

I have been involved in the Transnational STS Working Group. I am interested in fostering transnational organizational capacities in response to disasters.

I am especially interested in the following questions:  

    

pece_annotation_1473995548

tamar.rogoszinski
  1. I first looked up travel to and from Liberia during the Ebola outbreak, since it had been seized. There was a ban, which has since been lifted after, but people coming to and from West Africa are still screened and recommended to visit physicians. As of mid-2015 there wa still a 21 day monitoring period needed. http://www.infectioncontroltoday.com/news/2015/05/cdc-downgrades-travel…'
  2. I was interested if there had been any progress on treatment for Ebola, but found that the main form of treatment is supportive care. Doctors are informed to provide IV fluid and ensure that the patient's immune response and other bodily functions are functioning properly. A vaccine is being worked on but has not gone through a trial to prove safety and effectiveness. https://www.cdc.gov/vhf/ebola/treatment/index.html
  3. I looked further into the vaccine being produced for Ebola. Currently, there is a combined phase 2 and phase 3 trial occurring in Sierra Leone called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola). The study is unblinded, so patients know whether or not they have received the vaccine. The vaccine is a rVSV-ZEBOV, or recombinant Vesicular Stomatitis Virus Zaire ebolavirus vaccine. This vaccine is also being used in phase 2 and phase 3 trials in Guinea and Liberia http://www.cdc.gov/vhf/ebola/strive/qa.html